Cipla (CIPLA) | Financial Analysis & Statements
Cipla Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
68.4B
Gross Profit
46.7B
68.25%
Operating Income
15.3B
22.31%
Net Income
12.9B
18.89%
EPS (Diluted)
₹16.06
Balance Sheet Metrics
Total Assets
373.9B
Total Liabilities
61.0B
Shareholders Equity
312.9B
Debt to Equity
0.19
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Cipla Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 271.5B | 254.5B | 224.7B | 216.2B | 189.9B |
| Cost of Goods Sold | 97.6B | 95.9B | 89.6B | 92.3B | 80.2B |
| Gross Profit | 173.8B | 158.5B | 135.1B | 123.9B | 109.7B |
| Gross Margin % | 64.0% | 62.3% | 60.1% | 57.3% | 57.8% |
| Operating Expenses | |||||
| Research & Development | 3.8B | 4.3B | 3.9B | 2.7B | 1.3B |
| Selling, General & Administrative | 29.6B | 27.8B | 26.2B | 24.8B | 20.0B |
| Other Operating Expenses | 23.5B | 22.4B | 18.2B | 16.1B | 14.1B |
| Total Operating Expenses | 56.8B | 54.6B | 48.3B | 43.5B | 35.5B |
| Operating Income | 61.4B | 53.7B | 40.2B | 35.7B | 32.5B |
| Operating Margin % | 22.6% | 21.1% | 17.9% | 16.5% | 17.1% |
| Non-Operating Items | |||||
| Interest Income | 2.6B | 2.2B | 1.6B | 796.2M | 472.6M |
| Interest Expense | 440.2M | 711.3M | 945.6M | 1.0B | 1.5B |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 68.2B | 57.0B | 40.4B | 34.9B | 32.9B |
| Income Tax | 15.3B | 15.5B | 12.0B | 9.3B | 8.9B |
| Effective Tax Rate % | 22.4% | 27.1% | 29.8% | 26.7% | 27.0% |
| Net Income | 52.7B | 41.5B | 28.3B | 25.5B | 23.9B |
| Net Margin % | 19.4% | 16.3% | 12.6% | 11.8% | 12.6% |
| Key Metrics | |||||
| EBITDA | 74.3B | 66.9B | 51.1B | 47.1B | 43.8B |
| EPS (Basic) | ₹65.29 | ₹51.05 | ₹34.72 | ₹31.20 | ₹29.82 |
| EPS (Diluted) | ₹65.24 | ₹51.01 | ₹34.69 | ₹31.17 | ₹29.79 |
| Basic Shares Outstanding | 807552253 | 807291686 | 807007965 | 806668279 | 806358447 |
| Diluted Shares Outstanding | 807552253 | 807291686 | 807007965 | 806668279 | 806358447 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Cipla Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.9B | 6.4B | 6.3B | 6.8B | 7.9B |
| Short-term Investments | 100.2B | 71.4B | 56.4B | 39.5B | 29.5B |
| Accounts Receivable | 55.1B | 47.7B | 40.6B | 34.2B | 34.5B |
| Inventory | 56.4B | 52.4B | 51.6B | 53.5B | 46.7B |
| Other Current Assets | 10.5B | 9.0B | 72.9M | 88.0M | 93.1M |
| Total Current Assets | 232.9B | 194.4B | 172.7B | 147.3B | 132.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 52.6B | 50.7B | 49.9B | 51.6B | 49.6B |
| Goodwill | 82.6B | 78.3B | 75.0B | 79.8B | 78.4B |
| Intangible Assets | 17.2B | 16.0B | 15.3B | 17.0B | 18.3B |
| Long-term Investments | 117.6M | 83.1M | 0 | - | - |
| Other Non-Current Assets | 4.4B | 3.0B | 2.6B | 2.2B | 1.6B |
| Total Non-Current Assets | 141.0B | 132.8B | 121.9B | 123.7B | 119.4B |
| Total Assets | 373.9B | 327.2B | 294.6B | 271.0B | 251.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 28.4B | 24.7B | 25.3B | 25.1B | 20.7B |
| Short-term Debt | 1.9B | 3.3B | 5.9B | 4.8B | 6.1B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 431.3M | 1.4B | 529.3M | 461.5M | 619.0M |
| Total Current Liabilities | 54.8B | 52.5B | 51.1B | 49.1B | 45.9B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.5B | 2.3B | 2.1B | 5.7B | 14.0B |
| Deferred Tax Liabilities | 535.3M | 1.9B | 1.6B | 2.4B | 3.0B |
| Other Non-Current Liabilities | 78.9M | 180.6M | 204.1M | 125.0M | 134.5M |
| Total Non-Current Liabilities | 6.1B | 6.7B | 6.4B | 10.7B | 19.7B |
| Total Liabilities | 61.0B | 59.2B | 57.5B | 59.8B | 65.7B |
| Equity | |||||
| Common Stock | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Retained Earnings | 256.4B | 214.4B | 180.6B | 156.7B | 135.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 312.9B | 268.0B | 237.1B | 211.2B | 185.9B |
| Key Metrics | |||||
| Total Debt | 4.4B | 5.6B | 8.0B | 10.6B | 20.1B |
| Working Capital | 178.0B | 142.0B | 121.7B | 98.1B | 86.2B |
Balance Sheet Composition
Cipla Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 68.2B | 59.0B | 42.2B | 36.8B | 32.9B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 473.4M | 461.6M | 390.4M | 241.2M | 195.4M |
| Working Capital Changes | -11.2B | -9.7B | -5.4B | -5.4B | 1.7B |
| Operating Cash Flow | 55.2B | 48.1B | 36.5B | 31.8B | 35.8B |
| Investing Activities | |||||
| Capital Expenditures | -11.4B | -10.6B | -8.1B | -5.3B | -6.1B |
| Acquisitions | -2.4B | -2.2B | -251.3M | -180.2M | -110.5M |
| Investment Purchases | -22.0B | -17.0B | -13.5B | -14.2B | -16.6B |
| Investment Sales | 0 | 6.0M | 0 | 1.7B | - |
| Investing Cash Flow | -35.5B | -29.4B | -21.8B | -17.7B | -22.7B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -10.5B | -6.9B | -4.0B | -4.0B | - |
| Debt Issuance | 119.6M | - | - | 0 | 704.9M |
| Debt Repayment | -980.1M | -3.0B | -3.5B | -10.4B | -10.2B |
| Financing Cash Flow | -12.7B | -13.6B | -10.7B | -14.3B | -10.3B |
| Free Cash Flow | 34.6B | 27.8B | 20.5B | 26.2B | 29.4B |
| Net Change in Cash | 6.9B | 5.2B | 4.0B | -225.2M | 2.8B |
Cash Flow Trend
Cipla Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.20
Forward P/E
23.62
Price to Book
3.20
Price to Sales
3.77
PEG Ratio
-0.48
Profitability Ratios
Profit Margin
16.26%
Operating Margin
14.03%
Return on Equity
16.85%
Return on Assets
14.10%
Financial Health
Current Ratio
4.25
Debt to Equity
1.42
Beta
0.06
Per Share Data
EPS (TTM)
₹56.28
Book Value per Share
₹407.53
Revenue per Share
₹346.27
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CIPLA | 1.1T | 23.20 | 3.20 | 16.85% | 16.26% | 1.42 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Dr. Reddy's | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.





